24,639 Roche Holding AG $RHHBY Shares Purchased by First Command Advisory Services Inc.

First Command Advisory Services Inc. raised its stake in Roche Holding AG (OTCMKTS:RHHBY) by 188.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,694 shares of the company’s stock after buying an additional 24,639 shares during the quarter. First Command Advisory Services Inc.’s holdings in Roche were worth $1,956,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Puzo Michael J acquired a new stake in shares of Roche during the 2nd quarter valued at $1,229,000. North Star Asset Management Inc. purchased a new position in shares of Roche during the 2nd quarter valued at $1,351,000. S&CO Inc. increased its stake in shares of Roche by 163.0% in the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock worth $6,880,000 after acquiring an additional 87,107 shares during the last quarter. Opal Capital LLC acquired a new position in shares of Roche in the first quarter worth $4,448,000. Finally, Associated Banc Corp acquired a new position in shares of Roche in the third quarter worth $1,740,000.

Roche Price Performance

Roche stock opened at $60.57 on Thursday. Roche Holding AG has a one year low of $44.57 and a one year high of $61.75. The company’s fifty day moving average price is $56.28 and its two-hundred day moving average price is $53.97. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.23 and a quick ratio of 0.95.

Analyst Ratings Changes

RHHBY has been the topic of a number of recent research reports. UBS Group downgraded Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Deutsche Bank upgraded Roche from a “hold” rating to a “buy” rating in a report on Friday, October 23rd. HSBC reissued a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Finally, Royal Bank Of Canada started coverage on shares of Roche in a research note on Tuesday, September 8th. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Roche currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Roche Profile

Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions. Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.